Chronic Obstructive Pulmonary Disease is Responsible for 3 Million Deaths a Year in the World
This pathology has a significant impact on patients' lives, including physical, emotional and economic consequences
Regeneron, Sanofi's Dupixent Get FDA Approval For Chronic Obstructive Pulmonary Disease Treatment
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY), Friday announced that the U.S. Food and Drug Administration has approved
Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's lung", the companies said on Friday.
Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
Regeneron Pharmaceuticals and Sanofi have won FDA expanded approval of their blockbuster anti-inflammatory drug Dupixent in chronic obstructive pulmonary disease.
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
Key Takeaways Regeneron and Sanofi shares edged higher Friday after their drug to treat chronic obstructive pulmonary disease (COPD) received approval from the Food and Drug Administration (FDA).The drug,
FDA Approves Dupixent for Some Patients Struggling With COPD Symptoms
Dupixent may help some people with inadequately controlled COPD who have a type of lung inflammation that worsens symptoms.
Regeneron/ Sanofi granted FDA label expansion for Dupixent in COPD
Regeneron (REGN) and Sanofi's (SNY) asthma therapy Dupixent receives FDA approval for label expansion in treating certain patients with COPD. Read more here.
Regeneron, Sanofi blockbuster Dupixent wins FDA approval for COPD
Dupixent, commonly used to treat eczema and asthma, was cleared for a subset of patients with chronic obstructive pulmonary disease.
Sanofi blockbuster drug wins clearance in US for lung disease
Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after ...
FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease
On Friday, the FDA approved Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Dupixent (dupilumab) ...
Exclusive: Understanding Chronic Lung Diseases And Co-Morbidities
MP Cariappa, Public Health Specialist, Advisor, Tata Trusts shares inputs on understanding chronic lung diseases. He is also ...
Rising Kashmir8d
Understanding COPD: A Chronic Lung Disease
Chronic obstructive lung disease, also known as chronic obstructive pulmonary disease (COPD), is a general term for a group ...
Commit To Care: The Power of Adherence In Chronic Respiratory Disease Treatment
With asthma and chronic obstructive pulmonary disease (COPD) on the rise, worsened by air pollution, tobacco use, and ...
News Medical on MSN2d
Research reveals key role of mucin modification in muco-obstructive diseases
With each breath, a human may inhale thousands of harmful microbes into the lungs. Mucus, the gel-like moist substance ...
Too Old to Operate11d
Enhancing Pulmonary Rehabilitation in COPD with Virtual Reality
The following is a summary of “Virtual reality for COPD exacerbation: A randomized controlled trial,” published in the August ...
Medindia2d
Role of Mucin Sialylation in Muco-Obstructive Disorders
Discover how sugar modifications, particularly sialic acid, impact mucus formation and transport, contributing to diseases ...
Medscape3d
Loneliness/Disease Link Debatable?
Rather than a causal risk factor for diseases such as stroke, dementia, CVD, and psychiatric illness, loneliness may be a ...
Teesside University4d
Researchers reducing falls risk for people living with chronic disease
Researchers from Teesside University and the National Institute for Health and Care Research (NIHR) Applied Research ...